Staging of primary malignancies of bone

Ca-A Cancer Journal for Clinicians

Volumn 56, Issue 6, 2006, Pages 366-375

  Heck Jr , Robert K ^a   Peabody, Terrance D ^b   Simon, Michael A ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EWING SARCOMA; HISTOLOGY; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RISK FACTOR;

BONE NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SARCOMA;

EID: 33845430811     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.56.6.366     Document Type: Article

References (120)

1. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
2. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
3. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
4. Unni KK. Dahlin's Bone Tumors, 5th ed. Philadelphia, PA: Lippincott-Raven; 1996.
5. Berquist TH. Magnetic resonance imaging of musculoskeletal neoplasms. Clin Orthop Relat Res 1989;244:101-118.
6. Exner GU, von Hochstetter AR, Augustiny N, von Schulthess G. Magnetic resonance imaging in malignant bone tumours. Int Orthop 1990;14:49-55.
7. Jaramillo D, Laor T, Gebhardt MC. Pediatric musculoskeletal neoplasms. Evaluation with MR imaging. Magn Reson Imaging Clin N Am 1996;4:749-770.
8. Kalmar JA, Eick JJ, Merritt CR, et al. A review of applications of MRI in soft tissue and bone tumors. Orthopedics 1988;11:417-425.
9. Kransdorf MJ. Magnetic resonance imaging of musculoskeletal tumors. Orthopedics 1994;17:1003-1016.
10. Lang P, Johnston JO, Arenal-Romero F, Gooding CA. Advances in MR imaging of pediatric musculoskeletal neoplasms. Magn Reson Imaging Clin N Am 1998;6:579-604.
11. Massengill AD, Seeger LL, Eckardt JJ. The role of plain radiography, computed tomography, and magnetic resonance imaging in sarcoma evaluation. Hematol Oncol Clin North Am 1995;9:571-604.
12. Siegel MJ. Magnetic resonance imaging of musculoskeletal soft tissue masses. Radiol Clin North Am 2001;39:701-720.
13. Sundaram M, McDonald DJ. Magnetic resonance imaging in the evaluation of the solitary tumor of bone. Curr Opin Radiol 1990;2:697-702.
14. Vanel D, Verstraete KL, Shapeero LG. Primary tumors of the musculoskeletal system. Radiol Clin North Am 1997;35:213-237.
15. Kaste SC, Pratt CB, Cain AM, et al. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 1999;86:1602-1608.
16. Olson PN, Everson LI, Griffiths HJ. Staging of musculoskeletal tumors. Radiol Clin North Am 1994;32:151-162.
17. Peabody TD, Gibbs CP Jr, Simon MA. Evaluation and staging of musculoskeletal neoplasms. J Bone Joint Surg Am 1998;80:1204-1218.
18. Peh WC. The role of imaging in the staging of bone tumors. Crit Rev Oncol Hematol 1999;31:147-167.
19. Aoki J, Endo K, Watanabe H, et al. FDG-PET for evaluating musculoskeletal tumors: a review. J Orthop Sci 2003;8:435-441.
20. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219:774-777.
21. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-3206.
22. 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-518.
23. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003;32:201-208.
24. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol 2005;34:367-374.
25. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med Biol 1994;21:739-747.
26. Hoh CK, Scheipers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
27. Kalish JA, Babineau TJ. PET scans in tumor staging: hope or hype? Curr Surg 2006;63:8-12.
28. Lee FY, Yu J, Chang SS, et al. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. J Bone Joint Surg Am 2004;86-A:2677-2685.
29. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000;41:1695-1701.
30. Yanagawa T, Watanabe H, Inoue T, et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J Comput Assist Tomogr 2003;27:175-182.
31. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 2003;24:273-279.
32. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors. J Bone Joint Surg Am 1982;64:1121-1127.
33. Mankin HJ, Mankin CJ, Simon MA. The hazards of biopsy, revisited. J Bone Joint Surg Am 1996;78:656-663.
34. Heck RK, Stacy GS, Flaherty MJ, et al. A comparison study of staging systems for bone sarcomas. Clin Orthop Relat Res 2003;415:64-71.
35. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998;16:658-663.
36. Bielack S, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
37. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 2002;397:53-61.
38. Cotterill S, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
39. de Alava E, Antonescu C, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-799.
40. de Alava E, Kawai A, Healey J, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-1255.
41. Kolb E, Kushner B, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-3430.
42. Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004;429:286-291.
43. Marcus RB Jr, Berrey BH, Graham-Pole J, et al. The treatment of Ewing's sarcoma of bone at the University of Florida: 1969 to 1998. Clin Orthop Relat Res 2002;397:290-297.
44. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol 2001;23:340-348.
45. Harris M, Gieser P, Goorin A, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:3641-3648.
46. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on Neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-2018.
47. Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother 2001;13:324-330.
48. Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer 2005;104:1100-1109.
49. Marina NM, Pratt CB, Rao BN, et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992;70:2722-2727.
50. Campanacci M, Picci P, Gherlinzoni F, et al. Parosteal osteosarcoma. J Bone Joint Surg Br 1984;66:313-321.
51. Choong PF, Pritchard DJ, Rock MG, et al. Low grade central osteogenic sarcoma. A long-term followup of 20 patients. Clin Orthop Relat Res 1996;322:198-206.
52. Lewis VO, Gebhardt MC, Springfield DS. Parosteal osteosarcoma of the posterior aspect of the distal part of the femur. Oncological and functional results following a new resection technique. J Bone Joint Surg Am 2000;82A:1083-1088.
53. Ritschl P, Wurnig C, Lechner G, Roessner A. Parosteal osteosarcoma. 2-23-year follow-up of 33 patients. Acta Orthop Scand 1991;62:195-200.
54. Fiorenza F, Abudu A, Grimer R, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002;84:93-99.
55. Lee F, Mankin H, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81:326-338.
56. Ozaki T, Hillmann A, Lindner N, et al. Metastasis of chondrosarcoma. J Cancer Res Clin Oncol 1996;122:625-628.
57. Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis: a review of sixty-four cases. J Bone Joint Surg Am 2001;83:1630-1642.
58. Reith JD, Horodyski MB, Scarborough MT. Grade 2 chondrosarcoma: stage I or stage II tumor?, Clin Orthop Relat Res 2003;415:45-51.
59. Sheth DS, Yasko AW, Johnson ME, et al. Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 1996;78:745-750.
60. Capanna R, Bertoni F, Bettelli G, et al. Dedifferentiated chondrosarcoma. J Bone Joint Surg Am 1988;70:60-69.
61. Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004;86-A:2412-2418.
62. Frassica FJ, Unni KK, Beabout JW, Sim FH. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J Bone Joint Surg Am 1986;68:1197-1205.
63. Mercuri M, Picci P, Campanacci L, Rulli E. Dedifferentiated chondrosarcoma. Skeletal Radiol 1995;24:409-416.
64. Mitchell A, Ayoub K, Mangham D, et al. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br 2000;82:55-61.
65. Boriani S, Chevalley F, Weinstein J, et al. Chordoma of the spine above the sacrum. Treatment and outcome in 21 cases. Spine 1996;21:1569-1577.
66. Chandawarkar RY. Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg 1996;20:717-719.
67. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr. Lumbosacral chordoma. Prognostic factors and treatment. Spine 1999;24:1639-1645.
68. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993;72:714-718.
69. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am 2005;87:2211-2216.
70. Bergh P, Kindblom L, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000;88:2122-2134.
71. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11.
72. Meis JM, Raymond AK, Evans HL. "Dedifferentiated" chordoma. A clinicopathologic and immunohistochemical study of three cases. Am J Surg Pathol 1987;11:516-525.
73. Munshi HG, Merajver SD, Valdez R, et al. Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report. Am J Clin Oncol 2002;25:274-276.
74. Saito A, Hasegawa T, Shimoda T, et al. Dedifferentiated chordoma: a case report. Jpn J Clin Oncol 1998;28:766-771.
75. Thieblemont C, Biron P, Rocher F, et al. Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer 1995;31A:2255-2259.
76. Gebhardt MC, Lord FC, Rosenberg AE, Mankin HJ. The treatment of adamantinoma of the tibia by wide resection and allograft bone transplantation. J Bone Joint Surg Am 1987;69:1177-1188.
77. Hazelbag HM, Taminiau AH, Fleuren GJ, Hogendoorn PC. Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior. J Bone Joint Surg Am;1994;76:1482-1499.
78. Qureshi AA, Shott S, Mallin BA, Gitelis S. Current trends in the management of adamantinoma of long bones. An international study. J Bone Joint Surg 2000;82-A:1122-1131.
79. Papagelopoulos PJ, Galanis E, Frassica FJ, et al. Primary fibrosarcoma of bone. Outcome after primary surgical treatment. Clin Orthop Relat Res 2000;373:88-103.
80. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of malignant fibrous histiocytoma of bone. Orthopedics 2000;23:59-65.
81. Papagelopoulos PJ, Galanis EC, Trantafyllidis P, et al. Clinicopathologic features, diagnosis, and treatment of fibrosarcoma of bone. Am J Orthop 2002;31:253-257.
82. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000;18:4-11.
83. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol 2001;19:1818-1829.
84. Rosito P, Mancini AF, Rondelli R, et al. Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 1999;86:421-428.
85. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000;89:793-799.
86. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998;80:1020-1032.
87. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986;204:9-24.
88. Szendroi M, Papai Z, Koos R, Illes T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol 2000;73:87-94.
89. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Cancer 2003;97:3068-3075.
90. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
91. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21:536-542.
92. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000;18:2685-2694.
93. Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res 1982;167:250-254.
94. Malawer MM, Dunham WK. Skip metastases in osteosarcoma: recent experience. J Surg Oncol 1983;22:236-245.
95. Enneking WF, Kagan A. The implications of "skip" metastases in osteosarcoma. Clin Orthop Relat Res 1975;111:33-41.
96. Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004;426:92-96.
97. Wuisman P, Enneking WF. Prognosis for patients who have osteosarcoma with skip metastasis. J Bone Joint Surg Am 1990;72:60-68.
98. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-431.
99. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 1992;69:698-708.
100. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res 1997;345:206-214.
101. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-4027.
102. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St. Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001;19:171-182.
103. Meyers PA, Garlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-2458.
104. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
105. Argon A, Basaran M, Yaman F, et al. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. Jpn J Clin Oncol 2004;34:667-672.
106. Yonemoto T, Tatezaki S, Ishii T, et al. Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res 1998;349:194-199.
107. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori 2004;90:478-484.
108. Thompson RC Jr, Cheng EY, Clohisy DR, et al. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop Relat Res 2002;397:240-247.
109. Bacci G, Ferrari S, Longhi A, et al. Local and systemic control in Ewing's sarcoma of the femur treated with chemotherapy, and locally by radiotherapy and/or surgery. J Bone Joint Surg Br 2003;85:107-114.
110. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-1385.
111. Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res 2000;373:11-17.
112. Gorlick R, Huvos A, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
113. Uozaki H, Horiuchi H, Ishida T, et al. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997;79:2336-2344.
114. Sanders R, Drissi R, Billups C, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004;22:3790-3797.
115. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-577.
116. Kim H, Park Y, Oh JH, et al. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 2002;396:184-190
117. Hernandez-Rodriguez NA, Correa E, Sotelo R, et al. Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma. Cancer Detect Prev 2001;25:210-215.
118. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999;79:1185-1189.
119. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-1942.
120. Huang H, Illei P, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005;23:548-558.